Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

Vermeulen, M; van Doorn, P A; Brand, A; Strengers, P F; Jennekens, F G; Busch, H F
January 1993
Journal of Neurology, Neurosurgery & Psychiatry;Jan1993, Vol. 56 Issue 1, p36
Academic Journal
journal article
No abstract available.


Related Articles

  • Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien. Stangel, M.; Hartung, H.-P.; Gold, R.; Kieseier, B.C. // Der Nervenarzt;Jun2009, Vol. 80 Issue 6, p678 

    Long-term treatment of immune-mediated polyneuropathies remains difficult. For acute polyneuritis, or Guillain-Barré syndrome, the established standard therapy utilizes high doses of polyvalent intravenous immunoglobulins (IVIG). A recently published randomized placebo-controlled study of...

  • Dyshidrotic eczema following intravenous immunoglobulin treatment. Lee, Kachiu C.; Ladizinski, Barry // CMAJ: Canadian Medical Association Journal;8/6/2013, Vol. 185 Issue 11, pE530 

    The article discusses a case study of a 57-year-old man with chronic inflammatory demyelinating polyneuropathy having pruritic rash on his palms after treatment with intravenous immunoglobulin.

  • Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Bright, Richard J.; Wilkinson, Jenny; Coventry, Brendon J. // BMC Neurology;2014, Vol. 14 Issue 1, p1 

    Background Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immunemediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more than two months. Many individuals with chronic inflammatory demyelinating polyradiculoneuropathy fail...

  • Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker. Wakerley, Benjamin R.; Yuki, Nobuhiro // Journal of Neurology, Neurosurgery & Psychiatry;Aug2013, Vol. 84 Issue 8, p830 

    An introduction is presented in which the editors discuss an article related to the variability of serum immunoglobulin G (IgG) levels in patients who are receiving intravenous immunoglobulin (IVIG) for treating the chronic inflammatory demyelinating polyneuropathy (CIDP).

  • Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). Hirst, C.; Roasch, S.; Llewelyn, G.; Robertson, N. // Journal of Neurology, Neurosurgery & Psychiatry;Jun2006, Vol. 77 Issue 6, p800 

    The article describes a 19-year-old patient with intravenous immunoglobulin dependent relapsing chronic inflammatory demyelinating polyneuropathy. The patient achieved remission after treatment with alemtuzumab, a monoclonal antibody (MA) used for the treatment of B cell chronic lymphocytic...

  • Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. Deng, Chunqin; Hanna, Kim; Bril, Vera; Dalakas, Marinos; Donofrio, Peter; Doorn, Pieter; Hartung, Hans-Peter; Merkies, Ingemar // Journal of Neurology;Feb2012, Vol. 259 Issue 2, p348 

    Clinical equipoise is widely accepted as the basis of ethics in clinical research and requires investigators to be uncertain of the relative therapeutic merits of trial comparators. When clinical equipoise is in question, innovative trial designs are needed to reduce ethical tension while...

  • Pharma: Clinic Roundup.  // BioWorld Today;3/27/2012, Vol. 23 Issue 59, p8 

    The article presents an update on clinical trials, including the Polyneuropathy and Treatment with Hezentra (PATH) study by CSL Behring to evaluate two different doses of subcutaneous immunoglobulin in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

  • CITATIONS AND CLINICIANS' NOTES: NERVE AND MUSCLE.  // Current Medical Literature: Neurology;2005, Vol. 21 Issue 2, p37 

    Discusses the abstract of the study "Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone," by G. Lopate and colleagues.

  • Subcutaneous Immunoglobulin in Chronic Inlammatory Demyelinating Polyneuropathy. Latov, Norman // Neurology Alert;Jul2013, Vol. 31 Issue 11, p85 

    THE AUTHORS OF THIS STUDY TESTED THE EFFICACY OF SUBCUTANEOUS immunoglobulin (SCIG) as maintenance therapy in chronic inflammatory demyelinating polyneuropathy (CIDP). Twenty-nine patients on maintenance therapy with intravenous immunoglobulin (IVIG) for CIDP were randomized to either the same...

  • Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. Rajabally, Yusuf A. // Journal of Neurology, Neurosurgery & Psychiatry;Jun2014, Vol. 85 Issue 6, p631 

    Intravenous immunoglobulin therapy is of proven effect in chronic inflammatory neuropathies, including chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). In more recent years, there have been a number of anecdotal case reports and small series,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics